

ASCO 2022: Neue Daten und Trends für uroonkologische Tumore

Franz-Günther Runkel

Literatur

1. Stensland KD et al. Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments. *J Clin Oncol* 2022; 40 (suppl 16; abstr 5090)
2. Davis ID et al. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). *J Clin Oncol* 2022; 40 (suppl 17; abstr LBA5004)
3. Sandhu S et al. Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. *J Clin Oncol* 2022; 40 (suppl 16; abstr 5020)
4. Hofman MS et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). *J Clin Oncol* 2022; 40 (suppl 16; abstr 5000)
5. Loriot Y et al. Tumor agnostic efficacy and safety of erdafitinib in pts with advanced solid tumors with prespecified FGFR alterations in RAGNAR: Interim analysis results. *J Clin Oncol* 2022; 40 (suppl 16; abstr 3007)
6. Suarez C et al. Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER. *J Clin Oncol* 2022; 40 (suppl 16; abstr 4501)
7. Cella D et al. The relationship between HRQoL and clinical outcomes in patients with advanced renal cell carcinoma in CheckMate (CM) 214. *J Clin Oncol* 2022; 40 (suppl 16; abstr 4502)
8. Wang HT et al. TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma. *J Clin Oncol* 2022; 40 (suppl 16; abstr 4507)
9. Lu YT et al. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for pts with muscle-invasive bladder cancer in SWOG S1314. *J Clin Oncol* 2022; 40 (suppl 16; abstr 4506)